221 related articles for article (PubMed ID: 37717577)
1. Chronic Lymphocytic Leukemia: Disease Biology.
Koehrer S; Burger JA
Acta Haematol; 2024; 147(1):8-21. PubMed ID: 37717577
[TBL] [Abstract][Full Text] [Related]
2. Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.
Ten Hacken E; Burger JA
Biochim Biophys Acta; 2016 Mar; 1863(3):401-413. PubMed ID: 26193078
[TBL] [Abstract][Full Text] [Related]
3. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
Robak T; Robak P
Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253
[TBL] [Abstract][Full Text] [Related]
4. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
5. Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia--focus on the B-cell receptor.
ten Hacken E; Burger JA
Clin Cancer Res; 2014 Feb; 20(3):548-56. PubMed ID: 24323900
[TBL] [Abstract][Full Text] [Related]
6. Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies.
ten Hacken E; Burger JA
Pharmacol Ther; 2014 Dec; 144(3):338-48. PubMed ID: 25050922
[TBL] [Abstract][Full Text] [Related]
7. Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape.
Burger JA
Curr Opin Oncol; 2012 Nov; 24(6):643-9. PubMed ID: 22960555
[TBL] [Abstract][Full Text] [Related]
8. B cell receptor signaling in chronic lymphocytic leukemia.
Burger JA; Chiorazzi N
Trends Immunol; 2013 Dec; 34(12):592-601. PubMed ID: 23928062
[TBL] [Abstract][Full Text] [Related]
9. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.
de Rooij MF; Kuil A; Geest CR; Eldering E; Chang BY; Buggy JJ; Pals ST; Spaargaren M
Blood; 2012 Mar; 119(11):2590-4. PubMed ID: 22279054
[TBL] [Abstract][Full Text] [Related]
10. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
Till KJ; Pettitt AR; Slupsky JR
J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
[TBL] [Abstract][Full Text] [Related]
11. A Novel Triple-Action Inhibitor Targeting B-Cell Receptor Signaling and BRD4 Demonstrates Preclinical Activity in Chronic Lymphocytic Leukemia.
Smith AL; Eiken AP; Skupa SA; Moore DY; Umeta LT; Smith LM; Lyden ER; D'Angelo CR; Kallam A; Vose JM; Kutateladze TG; El-Gamal D
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743155
[TBL] [Abstract][Full Text] [Related]
12. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
Herman SE; Gordon AL; Hertlein E; Ramanunni A; Zhang X; Jaglowski S; Flynn J; Jones J; Blum KA; Buggy JJ; Hamdy A; Johnson AJ; Byrd JC
Blood; 2011 Jun; 117(23):6287-96. PubMed ID: 21422473
[TBL] [Abstract][Full Text] [Related]
13. Targeting the B cell receptor signaling pathway in chronic lymphocytic leukemia.
Patton JT; Woyach JA
Semin Hematol; 2024 Apr; 61(2):100-108. PubMed ID: 38749798
[TBL] [Abstract][Full Text] [Related]
14. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
Maddocks K; Jones JA
Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells.
Purroy N; Carabia J; Abrisqueta P; Egia L; Aguiló M; Carpio C; Palacio C; Crespo M; Bosch F
Oncotarget; 2017 Jan; 8(1):742-756. PubMed ID: 27888629
[TBL] [Abstract][Full Text] [Related]
16. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
Buchner M; Baer C; Prinz G; Dierks C; Burger M; Zenz T; Stilgenbauer S; Jumaa H; Veelken H; Zirlik K
Blood; 2010 Jun; 115(22):4497-506. PubMed ID: 20335218
[TBL] [Abstract][Full Text] [Related]
17. Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling.
Burger JA; Montserrat E
Blood; 2013 Feb; 121(9):1501-9. PubMed ID: 23264597
[TBL] [Abstract][Full Text] [Related]
18. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.
Quiroga MP; Balakrishnan K; Kurtova AV; Sivina M; Keating MJ; Wierda WG; Gandhi V; Burger JA
Blood; 2009 Jul; 114(5):1029-37. PubMed ID: 19491390
[TBL] [Abstract][Full Text] [Related]
19. Targeting the B cell receptor pathway in chronic lymphocytic leukemia.
Davids MS; Brown JR
Leuk Lymphoma; 2012 Dec; 53(12):2362-70. PubMed ID: 22616724
[TBL] [Abstract][Full Text] [Related]
20. CXCR4- and BCR-triggered integrin activation in B-cell chronic lymphocytic leukemia cells depends on JAK2-activated Bruton's tyrosine kinase.
Montresor A; Toffali L; Rigo A; Ferrarini I; Vinante F; Laudanna C
Oncotarget; 2018 Oct; 9(80):35123-35140. PubMed ID: 30416684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
